Durable clinical benefit of letrozole in leptomeningeal metastasis of breast cancer
Tóm tắt
A case of a woman in her 60s with breast cancer, whose leptomeningeal metastasis (LM) of breast cancer improved remarkably with letrozole monotherapy, is reported. The patient complained of numbness of her left hand and hoarseness, followed by progressive asymmetric extremity weakness and a bladder and rectal disturbance. The patient had undergone surgery for left breast cancer 18 years earlier and was concerned about recurrence of breast cancer, but there were no typical findings with some imaging modalities. The third lumbar puncture showed the malignant cytology of breast cancer, and the patient was diagnosed with recurrent breast cancer. Her performance status was very poor, and it was difficult to administer systemic chemotherapy. Letrozole was started because immunohistochemistry was positive for estrogen and progesterone receptors. After 4 months of letrozole therapy, the symptoms improved gradually. LM has a poor prognosis, and there is little evidence on which to base treatment, but hormone therapy may be an option for LM when the tumor is hormone receptor-positive, slow growing, and has a small volume.
Tài liệu tham khảo
Scott BJ, Oberheim-Bush NA, Kesari S (2016) Leptomeningeal metastasis in breast cancer—a systematic review. Oncotarget 7:3740–3747
Zoghi B, Elledge R (2016) Endocrine therapy for leptomeningeal metastases from ER-positive breast cancer: case report and a review of the literature. Breast J 22:218–223
Assi HI, Mahmoud T, Saadeh FS et al (2018) Management of leptomeningeal metastasis in breast cancer. Clin Neurol Neurosurg 172:151–159
Siegal T (1998) Leptomeningeal metastases: rationale for systemic chemotherapy or what is the role of intra-CSF-chemotherapy? J Neurooncol 38:151–157
Peronkides S, Onyenadum A, Starakis I et al (2011) Prolonged survival of neoplastic meningitis from breast cancer with letrozole and intrathecal methotrexate: a case report. J Neurooncol 101:509–511
Ozdogan M, Samur M, Bozcuk HS et al (2003) Durable Remission of leptomeningeal metastases of Breast Cancer with Letrozole: a case report and implications of biomarkers on treatment selection. Jpn J Clin Oncol 33:229–231
Niwińska A, Pogoda K, Michalski W et al (2018) Determinants of prolonged survival for breast cancer patient groups with leptomeningeal metastasis (LM). J Neurooncol 1:191–198
Navarro Martín LM, Ocaña Fernández A, Rodríguez Sánchez CA et al (2005) Durable clinical benefit with exemestane in leptomeningeal metastasis of breast cancer. Clin Transl Oncol 7:358–360
Chang EL, Lo S (2003) Diagnosis and management of central nervous system metastases from breast cancer. Oncologist 8:398–410
Boogerd W, van den Bent MJ, Koehler PJ et al (2004) The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer 40:2726–2733
Grossman SA, Finkelstein DM, Ruckdeschel JC et al (1993) Randomized prospective comparison of intraventricular methotrexate and thiotepa in patient s with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 11:561–569
Bokstein F, Lossos A, Siegal T (1998) Leptomeningeal metastasis from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer 82:1756–1763
Tanaka Y, Oura S, Yoshimasu T et al (2013) Response of meningeal carcinomatosis from breast cancer to capecitabine monotherapy: a case report. Case Rep Oncol 6:1–5
Boogerd W, Dorresteijn LD, van Der Sande JJ et al (2010) Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology 55:117–119
Staff NP, Bosch EP, Engelstad J et al (2010) Metastatic lobular breast adenocarcinoma presenting as cauda equina syndrome. J Peripher Nerv Syst 15:75–78
Singh SK, Bansal VK, Wiley EL et al (2013) Long-term survival in an untreated patient with leptomeningeal carcinomatosis from breast primary. Clin Neurol Neurosurg 115:362–364
Miyajima M, Kusuhara H, Takahashi K et al (2013) Investigation of the effect of active efflux at the blood–brain barrier on the distribution of nonsteroidal aromatase inhibitors in the central nervous system. J Pharm Sci 102:3309–3319
O’Sullivan CC, Davarpanah NN, Abraham J et al (2017) Current challenges in the management of breast cancer brain metastases. Semin Oncol 44:85–100